Scholarlink

<p><i>Klebsiella pneumoniae</i> is a leading cause of nosocomial infections, bacteremia, and worldwide mortality. Further, a drastic rise in antibiotic-resistant isolates poses an urgent threat to humanity. Unfortunately, despite its clinical importance, a licensed <i>K. pneumoniae</i> vaccine is not yet available. Here, we report on the production and characterization of the broadest <i>K. pneumoniae</i> capsule bioconjugate vaccine to date. We tested this vaccine for its immunogenicity, functionality, efficacy, and antibody durability against a variety of <i>K. pneumoniae</i> isolates in a murine bacteremia model. We also established an immunocompromised murine model of bacteremia to better recapitulate human infection and tested our vaccine’s efficacy in this background. The tetravalent capsule vaccine is highly immunogenic in mice, generating a robust immune response against all capsule types included (K1, K2, KL102, and KL107). Further, the generated antibodies persist for at least 6 months. The vaccine-induced antibodies are highly functional against a variety of clinical isolates of <i>K. pneumoniae</i>, including both classical and hypervirulent strains. Finally, the vaccine led to increased survival after bacteremia challenge compared to placebo-immunized mice. Our findings confirm that a capsule-based bioconjugate vaccine has clinical potential in preventing <i>K. pneumoniae</i> infections. These experiments signify much-needed progress towards a multivalent vaccine to combat this increasingly troublesome pathogen.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A multivalent capsule vaccine protects against Klebsiella pneumoniae bloodstream infections in healthy and immunocompromised mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月13日

查看全文
  • Paeton L. Wantuch,
  • Lloyd S. Robinson,
  • Cory J. Knoot,
  • Isra Darwech,
  • Aline M. Matsuguma,
  • Evgeny Vinogradov,
  • Nichollas E. Scott,
  • Christian M. Harding,
  • David A. Rosen

摘要

Klebsiella pneumoniae is a leading cause of nosocomial infections, bacteremia, and worldwide mortality. Further, a drastic rise in antibiotic-resistant isolates poses an urgent threat to humanity. Unfortunately, despite its clinical importance, a licensed K. pneumoniae vaccine is not yet available. Here, we report on the production and characterization of the broadest K. pneumoniae capsule bioconjugate vaccine to date. We tested this vaccine for its immunogenicity, functionality, efficacy, and antibody durability against a variety of K. pneumoniae isolates in a murine bacteremia model. We also established an immunocompromised murine model of bacteremia to better recapitulate human infection and tested our vaccine’s efficacy in this background. The tetravalent capsule vaccine is highly immunogenic in mice, generating a robust immune response against all capsule types included (K1, K2, KL102, and KL107). Further, the generated antibodies persist for at least 6 months. The vaccine-induced antibodies are highly functional against a variety of clinical isolates of K. pneumoniae, including both classical and hypervirulent strains. Finally, the vaccine led to increased survival after bacteremia challenge compared to placebo-immunized mice. Our findings confirm that a capsule-based bioconjugate vaccine has clinical potential in preventing K. pneumoniae infections. These experiments signify much-needed progress towards a multivalent vaccine to combat this increasingly troublesome pathogen.